Acheter Lucius Nintedanib en ligne

Plage de prix : EUR 73.67 à EUR 104.00

600+ vendus
Prix promo

Pharmacie physique à Hong Kong, authenticité 100% garantie

Points forts

PDGFR-α/β FGFR1-3 VEGFR1-3 CSF1R FLT-3 , 2014 10 IPF ,

Garanties de service

Expédition transfrontalièrePharmacie agrééeContrôle pharmacienGarantie authenticité

Caractéristiques

Spécification
100mg*60 150mg*60
Fabricant
Lucius Pharmaceuticals
Expédition
Hong Kong
SKU : ND Catégories : , Étiquette : Marque :

Informations produit

Nom anglais
Nintedanib
Nom générique
Nintedanib

Caractéristiques

Spécification
100mg*60 150mg*60
Fabricant
Lucius Pharmaceuticals
Expédition
Hong Kong

Détails complets

Indications

Used to treat idiopathic pulmonary fibrosis (IPF) in adults, chronic fibrosing interstitial lung disease (ILD) with a progressive phenotype in adults, and to slow the decline of lung function in adults with systemic sclerosis-associated interstitial lung disease (SSc-ILD).

Mécanisme d’action

, RTK nRTK RTK PDGFR α β FGFR 1 3 VEGFR 1 3 1 CSF1R Fms -3 FLT-3 FLT-3 , ILD ATP , , ILD

Pharmacologie

12.1 Mecanisme d action , (RTK) (nRTK) RTK (PDGFR) α β (FGFR) 1 3 (VEGFR) 1 3 1 (CSF1R) Fms -3 (FLT-3) FLT-3 , (ILD) (ATP) ,

Precautions

5.1 Child-Pugh B Child-Pugh C [ (8.6) (12.3)] Child-Pugh A [ Posologie (2.3)] 5.2 DILI , DILI

Interactions médicamenteuses

7.1 P- (P-gp) CYP3A4 P-gp , CYP3A4 [ (12.3)] P-gp CYP3A4 , 60% P-gp CYP3A4 [ (12.3)] ,

Effets indésirables

[ Precautions(5.2)] [ Precautions(5.3)] - [ Precautions(5.4)] [ Precautions(5.5)] [ Precautions(5.6)] [ Precautions(5.7)] [ Precautions(5.8)] 6.1 ,

Package Insert

Ingredients

11 , [ Mecanisme d action(12.1)] , 1H- -6- ,2,3- -3-[[[4-[ [(4- -1- ) ] ] ] ] ]-2- -, ,(3Z)-, (1:1) , C31H33N5O4ꞏC2H6O3S, 649.76 g/mol , 100 150 120.40 180.60 Medi

Indications

Used to treat idiopathic pulmonary fibrosis (IPF) in adults, chronic fibrosing interstitial lung disease (ILD) with a progressive phenotype in adults, and to slow the decline of lung function in adults with systemic sclerosis-associated interstitial lung disease (SSc-ILD).

Effets indésirables

[ Precautions(5.2)] [ Precautions(5.3)] - [ Precautions(5.4)] [ Precautions(5.5)] [ Precautions(5.6)] [ Precautions(5.7)] [ Precautions(5.8)] 6.1 ,

Precautions

5.1 Child-Pugh B Child-Pugh C [ (8.6) (12.3)] Child-Pugh A [ Posologie (2.3)] 5.2 DILI , DILI

Interactions médicamenteuses

7.1 P- (P-gp) CYP3A4 P-gp , CYP3A4 [ (12.3)] P-gp CYP3A4 , 60% P-gp CYP3A4 [ (12.3)] ,

Clinical Pharmacology

12 12.1 Mecanisme d action , (RTK) (nRTK) RTK (PDGFR) α β (FGFR) 1-3 (VEGFR) 1-3 1 (CSF1R) Fms -3 (FLT-3) FLT-3 , (ILD) ATP , , ILD nRTK Lck Lyn

Pharmacology and Toxicology

13 13.1 10 30 mg/kg/ MRHD AUC 4 , MRHD AUC, 100 mg/kg/ 3 ,

Clinical Studies

14 14.1 II 1 [NCT00514683] III 2 [NCT01335464] 3 [NCT01335477] 1231 (IPF) , , 150 mg 52 2 3 1 3:2 1 1:1 150 mg , 52

Avis produit (14)

Filtre : Tous les avis
4.8★★★★★
14 avis clients11 achats verifies
+o***e· il y a 3 semaines
★★★★
+t***3· il y a 1 mois
Achat verifie
★★★★★

Description

Indications

Used to treat idiopathic pulmonary fibrosis (IPF) in adults, chronic fibrosing interstitial lung disease (ILD) with a progressive phenotype in adults, and to slow the decline of lung function in adults with systemic sclerosis-associated interstitial lung disease (SSc-ILD).

Mécanisme d’action

, RTK nRTK RTK PDGFR α β FGFR 1 3 VEGFR 1 3 1 CSF1R Fms -3 FLT-3 FLT-3 , ILD ATP , , ILD

Pharmacologie

12.1 Mecanisme d action , (RTK) (nRTK) RTK (PDGFR) α β (FGFR) 1 3 (VEGFR) 1 3 1 (CSF1R) Fms -3 (FLT-3) FLT-3 , (ILD) (ATP) ,

Precautions

5.1 Child-Pugh B Child-Pugh C [ (8.6) (12.3)] Child-Pugh A [ Posologie (2.3)] 5.2 DILI , DILI

Interactions médicamenteuses

7.1 P- (P-gp) CYP3A4 P-gp , CYP3A4 [ (12.3)] P-gp CYP3A4 , 60% P-gp CYP3A4 [ (12.3)] ,

Effets indésirables

[ Precautions(5.2)] [ Precautions(5.3)] - [ Precautions(5.4)] [ Precautions(5.5)] [ Precautions(5.6)] [ Precautions(5.7)] [ Precautions(5.8)] 6.1 ,

Informations complementaires

Specification

100mg*60粒, 150mg*60粒